Saad Kareem 4
4 · GeneDx Holdings Corp. · Filed Oct 23, 2023
Insider Transaction Report
Form 4
Saad Kareem
Chief Business Officer
Transactions
- Exercise/Conversion
Restricted Stock Unit
2023-10-19−546→ 2,729 total→ Class A Common Stock (546 underlying) - Exercise/Conversion
Class A Common Stock
2023-10-19+546→ 18,705 total - Sale
Class A Common Stock
2023-10-20$3.44/sh−164$564→ 18,541 total
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
- [F2]The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction.
- [F3]3/16th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on January 19, 2022, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.